Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nanchang Hongyi Pharmaceutical Co., Ltd. /Nanchang Hongyi Technology Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20232499 | P1 |
Recruiting |
Small Cell Lung Cancer|Renal Cell Carcinoma|Non-Small-Cell Lung Cancer |
None |